AI-generated summary
This narrative review examines photobiomodulation, a non-invasive treatment using visible and near-infrared light, as a possible adjunct for Parkinson's disease. The authors report that preclinical studies suggest effects on mitochondrial function, neuroinflammation and dopaminergic neuron survival, while clinical evidence is preliminary and inconsistent. They conclude that photobiomodulation should be regarded as an investigational strategy, not an established therapy.
- Who or what was studied
- Parkinson's disease; experimental (preclinical) PD models and preliminary clinical observations
- Limits stated in the abstract
- The abstract notes small clinical sample sizes, heterogeneous intervention protocols, inconsistent controlled-trial outcomes, and sparse direct evidence on alpha-synuclein aggregation.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Neuroinflammation, Near-infrared, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.